Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients

J Heart Lung Transplant. 2008 Jul;27(7):804-7. doi: 10.1016/j.healun.2008.03.023. Epub 2008 May 19.

Abstract

We present 6 cases of multidrug-resistant (MDR) Acinetobacter baumannii pneumonia in lung transplant recipients. All cases were treated with imipenem and/or non-traditional antibiotics, such as tigecycline and colistimethate, and had different microbiologic and clinical outcomes. Prior treatment with broad-spectrum anti-microbial therapy was the single most likely risk factor for the development of infection due to MDR Acinetobacter baumannii. Ideal preventive and therapeutic strategies for this pathogen in lung transplant recipients require further study.

Publication types

  • Case Reports

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / microbiology*
  • Acinetobacter baumannii
  • Anti-Infective Agents / therapeutic use*
  • Colistin / analogs & derivatives
  • Colistin / therapeutic use
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Humans
  • Imipenem / therapeutic use
  • Lung Transplantation / adverse effects*
  • Male
  • Minocycline / analogs & derivatives
  • Minocycline / therapeutic use
  • Pneumonia / drug therapy*
  • Pneumonia / microbiology*
  • Risk Factors
  • Tigecycline
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Tigecycline
  • Imipenem
  • colistinmethanesulfonic acid
  • Minocycline
  • Colistin